Stockwinners Market Radar for February 19, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:58 EST Ovintiv sees FY20 capital investment of $2.7B, down 6% from FY19 - Sees FY20 crude oil and condensate volumes growing 4% year-over-year to 229 - 239 Mbbls/d.

20:14 EST Tocagen, Forte Biosciences to merge - Tocagen and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. Upon stockholder approval, the combined company is expected to operate under the name Forte Biosciences and trade on the Nasdaq Capital Market under the ticker symbol FBRX. Forte's lead asset, FB-401, is a potentially first-in-class, live biotherapeutic being developed as a topical therapy for the treatment of inflammatory skin diseases, including atopic dermatitis. In a Phase 1/2a trial in adults and pediatrics, FB-401 demonstrated significant efficacy and a favorable safety and tolerability profile. The full trial results will be submitted for publication in a peer-reviewed journal in the first half of 2020. A randomized Phase 2 trial is planned to commence in mid-2020 in adults and pediatrics with atopic dermatitis, providing an expected data readout in mid-2021.

20:07 EST Pan American Silver reports Q4 silver output 6.6M oz. vs. 6.1M last year - Reports Q4 gold output 173.9K oz vs. 37.2K last year.

19:10 EST Fly Intel: After Hours Movers - UP AFTER EARNINGS: Stamps.com (STMP) up 31.4%... ServiceSource (SREV) up 16.1%... Zillow Group (Z) up 15.1%... Avis Budget (CAR) up 12.3%... Community Health (CYH) up 11.0%... Noble Corp (NE) up 11.0%... ManTech (MANT) up 9.4%... Cimarex Energy (XEC) up 8.2%... CyberOptics (CYBE) up 7.8%... Ultra Clan (UCTT) up 7.3%... Trinity Industries (TRN) up 6.3%... MagnaChip Semi (MX) up 4.8%... Imax Corp (IMAX) up 3.8%... SM Energy (SM) up 3.6%... Green Dot (GDOT) up 3.2%... Sleep Number (SNBR) up 3.0%... Pioneer Natural (PXD) up 2.7%... Superior Energy (SPN) up 2.7%... nLight (LASR) up 2.6%... Aerojet Rocketdyne (AJRD) up 2.6%... Sunoco (SUN) up 2.4%... Masimo Corp (MASI) up 1.5%... Albemarle (ALB) up 1.3%. DOWN AFTER EARNINGS: Tivity Health (TVTY) down 33.7%... OraSure Technologies (OSUR) down 15.7%... Invitae (NVTA) down 10.9%... Boston Beer Co (SAM) down 9.1%... Brightcove (BCOV) down 8.7%... Grand Canyon Education (LOPE) down 7.2%... Grand Canyon Education (LOPE) down 7.2%... SpartanNash (SPTN) down 6.2%... CVR Partners (UAN) down 5.5%... America's Carmart (CRMT) down 3.5%... Q2 Holdings (QTWO) down 3.2%... Inovalon (INOV) down 3.2%... Synopsys (SNPS) down 3.0%... Reata Pharma (RETA) down 2.3%... Cheesecake Factory (CAKE) down 2.2%... CyrusOne (CONE) down 2.1%... Valmont Industries (VMI) down 2.0%... Jack in the Box (JACK) down 1.8%... Hyatt (H) down 1.3%... Tenaris (TS) down 1.3%. ALSO LOWER: Axovant Gene Therapies (AXGT) down 11.6% after equity offering... BioXcel Therapeutics (BTAI) down 10.1% after equity offering... Heron Therapeutics (HRTX) down 8.6% after FDA extended review period for HTX-011 NDA... Independence Realty Trust (IRT) down 4.6% after equity offering... Teva Pharma (TEVA) down 4.1% after Phase 2/3 trials in deutetrabenazine failed to meet the primary endpoints. Movers as of 18:30ET.

19:01 EST Embraer enters pact with DOJ to extend external monitorshop - Embraer S.A. informed its shareholders and the market that following the company's Material Facts from May 19, 2015, July 29, 2016, October 12, 2016 and October 24, 2016, Embraer and the U.S. Department of Justice agreed to extend the term of the external and independent monitorship carried out in the context of the deferred prosecution agreement entered into with the DOJ for an additional ninety days, in order to allow the monitor to complete his review. As result of the Extension, the DPA shall also have its term extended for an additional ninety days. The Extension aims to allow the conclusion of the review in connection with the external and independent monitorship carried out to evaluate the fulfillment, by Embraer, of the definitive agreements entered into with the DOJ and the Securities and Exchange Commission for the resolution of the allegations of violations of the Foreign Corrupt Practices Act. With the Extension, the external and independent monitorship and the DPA's term shall end on April 22, 2020.

18:29 EST SPDR Gold Shares holdings rise to 931.60MT from 929.84MT - This is the third consecutive increase and the highest level of holdings since November of 2016.

18:17 EST Alamos Gold sees FY20 gold production 425-465K oz vs. 494.5K oz in FY19

18:03 EST Ottawa Bancorp raises quarterly dividend, declares special cash dividend - Ottawa Bancorp announced that its Board of Directors has declared a one-time special cash dividend of 35c per share on its outstanding stock. Additionally, its Board of Directors has approved an increase in the company's quarterly cash dividend from 6c per share to 8c per share. The increased quarterly cash dividend and the special cash dividend will be paid on or about March 18 to stockholders of record as of the close of business on March 4.

18:02 EST Ascena Retail completes Dressbarn wind-down - Ascena Retail announced that the Dressbarn brand has completed the orderly wind down of its business operations, closing over 650 stores and successfully eliminating over $300M of lease liability.

17:49 EST CenterPoint Energy names John W. Somerhalder II interim president, CEO - CenterPoint Energy announced that its board of directors has appointed John W. Somerhalder II as interim President and Chief Executive Officer to succeed Scott M. Prochazka, who has stepped down as President and Chief Executive Officer, and as a member of the board of directors. Somerhalder is a 40-year energy industry veteran, including as Chief Executive and a Director of AGL Resources Inc., a natural gas utility. He has served as a Director of CenterPoint Energy, Inc. since 2016 and also serves as Director and Trustee on the boards of numerous non-profit organizations. The company has commenced a process to identify a permanent CEO and has formed a sub-committee of the board to support the selection process. These changes are effective immediately.

17:41 EST Valmont CEO says 2020 off to 'solid start' - CEO Kaniewski says: "We are off to a solid start in 2020. Sales and earnings growth is being driven by our infrastructure businesses, supported by solid backlogs. In the Engineered Support Structures segment, transportation market demand from continued government investments in infrastructure development will drive growth. In the wireless communication market, capital investments for 5G deployment will be somewhat delayed due to the T-Mobile/Sprint integration; however, we anticipate spending to increase in the second half of the year, accelerating into 2021. Considering these well-known delays and our record growth in 2019, we expect wireless communication sales to approach a 10.0% growth rate in 2020. Construction end-markets in Australia remain at recessionary levels and are not expected to significantly improve this year, impacting our Access Systems business. Our Utility segment entered the year with a record global backlog of nearly $500.0 million, supported by very strong market demand from ongoing investments in grid hardening and renewable energy sources. Strategic capacity additions in our North American steel structures plants are expected to increase volumes by approximately 5.0%, mostly in the second half of the year. We expect sales in our Coatings business to be similar to 2019 assuming relatively stable global industrial production levels. In the Irrigation segment, grower sentiment appears to be stabilizing in 2020, but we are not seeing a meaningful turnaround in demand as net farm income levels remain muted. Therefore, we are now projecting segment sales to be flat to down approximately 3.0% compared to 2019. While there is uncertainty around international projects, we are seeing continued market strength in Brazil. Our unwavering commitment to continuous improvement and delivering higher returns on invested capital requires us to strategically position our businesses for long-term profitable growth. As such, we are continuing to evaluate some of the more challenged product lines across all segments, including Access Systems in Australia. We look forward to sharing more details next quarter."

17:35 EST Zillow up 13% to $61.90 after Q4 results, Q1 revenue guidance beat estimates

17:33 EST Cushman & Wakefield acquires Colvill Office Properties, terms undisclosed - Cushman & Wakefield announced that the firm has acquired Colvill Office Properties, a provider of office agency leasing services in Houston. Colvill Office Properties currently directs leasing and marketing efforts for 17M square feet of Class-A office space in Houston. The Colvill Office Properties team has more than 130 collective years of experience and is a four-time recipient of the Owner's Representative of the Year award as voted by the Houston Office Leasing Broker's Association. The Colvill current portfolio includes more than 30 individual properties.

17:25 EST Alleghany declares special cash dividend of $15.00 per share - Alleghany's Board of Directors declared a special cash dividend of $15.00 per share for shareholders of record on March 5, payable on March 16.

17:22 EST Enzo Biochem's board increase proposal receives negative recommendation from ISS - Enzo Biochem shareholders Harbert Discovery Fund and Harbert Discovery Co-Investment Fund I, collectively HDF, the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, announced that proxy advisory firm ISS has recommended that shareholders vote against Enzo's proposal to amend its bylaws in order to increase the size of the Board and re-nominate Barry Weiner. Enzo's delayed 2019 Annual Meeting of Shareholders is scheduled for February 25. The analysis from ISS states, among other things: "A deeper review reveals modifications that appear to constitute an eleventh-hour attempt to salvage a board seat for Weiner in light of what appears to be strong shareholder support for the dissident nominees. Given the timing of the announcement - three days before the scheduled Annual General Meeting and after an apparently strong showing of support for the dissident nominees -, the board's assertion that it is somehow shareholder friendly is not only misleading, but arguably deceptive. (...) "The proposed increase in board size appears to be a late-stage entrenchment maneuver in response to what appears to have been robust support for the dissident campaign... (...) Given that it is unclear how this would be a net benefit to shareholders, support AGAINST this proposal is warranted".

17:16 EST B&G Foods acquires Farmwise, terms not disclosed - B&G Foods announced that effective February 19, it has acquired Farmwise, creator of Veggie Fries, Veggie Tots and Veggie Rings. B&G Foods funded the acquisition with cash on hand. Terms of the transaction were not disclosed.

17:08 EST Hepion Pharmaceuticals announces results from CRV431 in vitro studies - Hepion Pharmaceuticals announced results from in vitro studies showing that CRV431 can decrease production of the extracellular matrix, or ECM, molecules, collagen and fibronectin, from fibroblastic cells derived from five different organs. Collagen and fibronectin over-production from these types of cells cause fibrotic scarring of injured organs, and therefore these results suggest that CRV431 could exert anti-fibrotic activity across a range of diseases. The five cell types included in this study were lung fibroblasts from a patient with idiopathic pulmonary fibrosis, or IPF, cardiac fibroblasts, dermal fibroblasts, renal mesangial cells, and the LX2 hepatic stellate cell line. CRV431 dose-dependently decreased procollagen and fibronectin secretion from all cell types with similar magnitude, as measured by enzyme-linked immunosorbent assay, or ELISA. The extent of inhibition was similar whether or not the cells were stimulated with the profibrotic agent, transforming growth factor-beta, consistent with direct effects on ECM synthesis. CRV431 dose-dependently decreased ECM production by up to 55% at clinically relevant concentrations, without causing any reduction in cell viability. CRV431 is believed to reduce ECM production by inhibiting cyclophilin B, and consistent with this hypothesis, downregulation of cyclophilin B with small interfering RNA similarly decreased procollagen and fibronectin secretion.

16:59 EST Enservco announces NYSE approval of plan to regain compliance - Enservco announced that the NYSE has approved the company's plan to regain compliance with the NYSE's continued listing standard related to stockholders' equity. Accordingly, Enservco's common stock will continue to be listed on the NYSE pursuant to an extension. The company is not in compliance with sections 1003 and of the NYSE's company guide in that it has reported stockholders' equity of less than $2M as of September 30, 2019, and reported losses from continuing operations and/or net losses in its four most recent fiscal years. The company's compliance plan calls for Enservco to achieve a stockholders' equity balance of at least $6M by June 3, 2021. Under terms of the extension, Enservco will be required to demonstrate progress toward its stockholders' equity compliance plan and to provide the NYSE with quarterly updates.

16:45 EST RE/MAX Holdings raises quarterly dividend to 22c from 21c per share - The dividend is payable on March 18 to shareholders of record at the close of business on March 4.

16:43 EST Foot Locker raises quarterly dividend 5% to 40c per share - Payable on May 1 to shareholders of record on April 17.

16:43 EST SM Energy sees 2020 oil production up 5%-10%

16:41 EST First Interstate declares special dividend of 60c per share - The special dividend is payable on March 12, 2020 to owners of record as of March 2, 2020.

16:41 EST Host Hotels sees increase in hotel-level operating expenses in 2020 - For 2020, the Company expects slight improvement in year-over-year comparable hotel RevPAR driven by increased group revenues as its portfolio is expected to benefit from a more favorable citywide convention calendar. The Company expects leisure travel to support transient revenues as consumer confidence remains strong and the labor market is healthy, while business travel is expected to remain subdued given macroeconomic uncertainties. Additionally, the Company expects above inflationary growth in hotel-level operating expenses, primarily due to wages and benefits increases, to result in lower operating margins.

16:40 EST Elan to divest worlwide rights for Vecoxan for $55M in all cash deal - Elanco Animal Health Incorporated (ELAN) annouonced it signed an agreement with Merck Animal Health (MRK) to divest worldwide rights for Vecoxan for $55 million in an all-cash deal. Vecoxan is used for prevention and treatment of coccidiosis in calves and lambs. Divesting the rights to Vecoxan brings divestitures to-date into the $120 million to $140 million revenue range Elanco previously stated it expected across both companies. In total, these divestitures have generated approximately $425 million in pre-tax proceeds, which will be used to pay down debt associated with the transaction. The closing of the transaction with Vecoxan is contingent on Elanco closing its transaction with Bayer, as well as other customary closing conditions. Elanco is in advanced discussions with the required regulatory authorities, which are progressing as expected. Elanco already received antitrust clearance for the transaction in China, Turkey and Ukraine. Any proposed remedy and final clearance for the Elanco/Bayer transaction remains subject to review and approval from other regulatory authorities.

16:34 EST EnPro raises quarterly dividend to 26c from 25c per share - The dividend is payable on March 18, 2020 to shareholders of record as of the close of business on March 4, 2020.

16:30 EST Invesco Mortgage raises quarterly dividend 11.1% to 50c per share

16:26 EST Noble Corp. says Robert Eifler to succeed Julie Robertson as President and CEO - Noble Corporation announced that its Board of Directors is implementing a leadership transition plan that capitalizes on the strength of Noble's management team. At the close of the company's next annual general meeting of shareholders, Julie Robertson will resign as President and CEO, and will take on the newly created role of an executive Chairman of the Company's Board of Directors. Robert Eifler, who first joined Noble in 2005 and currently serves as Senior Vice President, Commercial, will become President and CEO. Eifler will stand for election to the Board of Directors at the upcoming annual general meeting. Eifler joined Noble in 2005 as part of the Company's management development program working offshore and in various operational roles and has held numerous operational and marketing roles with increasing responsibility around the world. He currently serves as Noble's Senior Vice President, Commercial.

16:26 EST Xcel Energy names Bob Frenzel COO, Brian Van Abel CFO - Xcel Energy's chairman, president and CEO, announced that Bob Frenzel will be named president and chief operating officer and that Brian Van Abel will be the company's chief financial officer, both effective March 31. As president and COO, Frenzel will have oversight for Xcel Energy's four operating companies, including the company's transmission, distribution and natural gas operations. He will continue to report to Fowke, chairman and CEO. Van Abel will become Xcel Energy's executive vice president and chief financial officer. Van Abel is currently serving as senior vice president, Finance and Corporate Development. Fowke also announced several key leadership changes. Tim O'Connor will become executive vice president and chief generation officer effective March 31. O'Connor currently serves as the company's chief nuclear officer, a role he has held for the past eight years. During that time, the company's nuclear fleet has become the top performing nuclear generating fleet in the nation. O'Connor will retain oversight of nuclear operations in his new expanded role. In addition, Wendy Mahling has been named vice president and Corporate Secretary, replacing Judy Poferl, who will retire March 31, Karen Hyde has been named senior vice president, chief risk, audit and compliance officer, and Frank Prager has been named senior vice president of Strategy, Planning and External Affairs.

16:25 EST TPG Specialty Lending raises quarterly dividend to 41c from 39c per share

16:23 EST Magnolia Oil & Gas sees FY20 capital outlays down 5%-10% - The company states: "For 2020, we expect to spend approximately 60% of our adjusted EBITDAX for drilling and completing wells, which is consistent with our business model. While we anticipate drilling and completing a similar number of wells this year as compared to 2019, improved efficiencies of our drilling program combined with lower oil field service costs should reduce our overall capital outlays by 5% to 10% compared to last year. We estimate that this year's capital and activity program should result in year-over-year total production growth of approximately 5%, including growth in Giddings oil production of more than 20 percent. Based on the pace of our capital spending and estimated non-operated activity, we expect a similar pattern for our quarterly production profile as compared to 2019 - with higher spending and activity levels in the early part of the year, followed by higher production during the second and third quarters. We currently plan to shift our Karnes area rig to Giddings in the latter part of the year to start an early stage development program while continuing with our appraisal efforts. Capital spending levels are expected to peak in the first quarter and then gradually decline through the remainder of the year. We expect our first quarter 2019 production to average around 65 Mboe/d, as most of the wells turned in line are expected to occur in the latter part of the quarter."

16:22 EST Energy Transfer LP announces multi-basin strategic alignment - Energy Transfer LP announced the execution of a suite of gathering, processing, transportation and fractionation agreements with a large, investment- grade integrated energy company. These agreements increase and extend long-term commitments between the company and Energy Transfer in the Eagle Ford and Delaware Basins through 2034 and 2040, respectively.

16:20 EST Community Health CEO sees incremental growth in 2020 - Wayne T. Smith, chairman and CEO of Community Health Systems, said, "We concluded 2019 with a strong finish to the year. Our successful divestiture program, along with strategic growth initiatives in our core portfolio of markets, has driven better results, including improved same-store volume and net revenue growth in 2019. As we enter 2020, we expect to deliver incremental growth, driven by a combination of continued same-store net revenue performance and execution across our strategic margin improvement programs."

16:15 EST Pioneer Natural sees Q1 production 217-227 MBOPD - First quarter 2020 oil production is forecasted to average between 217 to 227 MBOPD and total production to average between 361 to 376 MBOEPD. Production costs are expected to average $8.25 per BOE to $10.25 per BOE. DD&A expense is expected to average $12.50 per BOE to $14.50 per BOE. Total exploration and abandonment expense is forecasted to be $10 million to $20 million. G&A expense is expected to be $72 million to $82 million. Interest expense is expected to be $30 million to $35 million. Other expense is forecasted to be $20 million to $30 million. Accretion of discount on asset retirement obligations is expected to be $2 million to $5 million. The cash flow impact related to purchases and sales of oil and gas, including firm transportation, is expected to be zero to a loss of $50 million. The Company's effective income tax rate is expected to range from 21% to 25%. Current income taxes are expected to be less than $5 million.

16:11 EST Integer acquires Inomec, terms undisclosed - Integer announced it has acquired Inomec, formally establishing its presence in Israel. The acquisition enables Integer to create a research and development and sales center in the region, and adds catheter design, clinical, and pilot manufacturing capabilities to its portfolio. Founded in 2008, Inomec specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, metal implants, drug-device combination devices, and laser processing services. Capabilities include clinical and pilot manufacturing, clean room assembly and packaging services, polymer and metallic laser welding, and bio-compatible 3D printing.

16:08 EST Teva's Phase 2/3 trials in deutetrabenazine failed to meet the primary endpoints - Teva announced the Phase 2/3 ARTISTS 1 and Phase 3 ARTISTS 2 trials designed to evaluate deutetrabenazine compared to placebo for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome failed to meet the primary endpoint of reduction in motor and phonic tics as assessed by the Total Tic Score of the Yale Global Tic Severity Scale. In the data received this week, the most commonly reported adverse event in the ARTISTS 1 and ARTISTS 2 studies were headache, somnolence and fatigue. In this population, no new safety signals were identified that were inconsistent with the known safety profile of deutetrabenazine. Deutetrabenazine was approved by the FDA as AUSTEDO tablets for the treatment of chorea associated with Huntington's disease in April 2017 and for tardive dyskinesia in adults in August 2017.

16:06 EST Pioneer Natural raises quarterly dividend to 55c from 44c per share - The dividend is payable April 14, 2020, to stockholders of record at the close of business on March 31, 2020.

16:03 EST Crowdstrike names Michael Sentonas CTO - CrowdStrike announced the appointment of Michael Sentonas as the company's new chief technology officer effective immediately. Sentonas, who most recently served as the vice president of technology strategy at CrowdStrike, is replacing Dmitri Alperovitch, who has transitioned out of the company.

16:02 EST Tivity Health CEO Donato Tramuto departs, Bob Greczyn named interim CEO - Tivity Health announced that Donato Tramuto will depart as CEO and resign from the Board, effective immediately. The Board has appointed current Director Robert Greczyn, Jr. Interim CEO while it conducts a comprehensive CEO search with the assistance of a leading executive search firm. Greczyn has been a member of the Board since 2015 and has over 30 years of experience in leadership roles in managed care and healthcare at some of the nation's leading organizations.

14:33 EST Fidelity D and D Bancorp Inc trading resumes

14:28 EST Fidelity D and D Bancorp Inc trading halted, volatility trading pause

14:16 EST Abbott recalls NC catheters due to failure of balloon to deflate - Abbot Vascular is recalling the NC Trek RX Coronary Dilatation Catheter and NC Traveler RX Coronary Dilatation Catheters, balloon diameters 4.0mm, 4.5mm and 5.0mm because the balloons from the impacted lots may not deflate as intended. This issue is due to weaker material close to the balloon bond resulting from excessive exposure to heat during manufacturing. Use of these devices may cause serious adverse health consequences, such as prolonged cardiac ischemia, air embolism, thrombosis, myocardial infarction, and additional surgery that could lead to post-operative complications, including death. Abbot Vascular has received 13 complaints related to this issue. One death has been reported. The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death, the FDA said. The recalled products were distributed between August 2019 and January 2020, and 13,891 devices are being recalled in the U.S., according to the FDA.

13:58 EST Sony cancels participation at PAX East over coronavirus concerns - Sony Interactive Entertainment said in an update to a blog post that it has made the decision to cancel its participation at PAX East in Boston this year due to increasing concerns related to COVID-19. "We felt this was the safest option as the situation is changing daily," the company said. "We are disappointed to cancel our participation in this event, but the health and safety of our global workforce is our highest concern." Reference Link

13:46 EST Tyson Foods reports resignation of Chief Accounting Officer Gibbs - In a regulatory filing earlier, Tyson Foods disclosed that on February 13, Stephen Gibbs, Senior Vice President and Chief Accounting Officer, notified the company of his intent to accept employment with another employer and, in connection therewith, resign from his positions as an officer and employee of the company effective February 21. "Gibbs's resignation is not the result of any disagreement with the Company regarding its operations, policies or practices," the filing stated.

13:33 EST Tyson Foods says has seen sixfold increase in pork exports in China - Says has seen sixfold increase in pork exports to China vs. the same quarter in the previous year. Despite some temporary challenges related to coronavirus, Tyson says it expects the interest to endure. Comments taken from CAGNY Conference.

13:23 EST Google Cloud acquires Cornerstone Technology - Howard Weale, Director, Transformation Practice, announced in a Google blog post that Google Cloud has acquired Cornerstone Technology to better help customers migrate their mainframe workloads to Google Cloud. "Cornerstone brings a wealth of experience and innovative solutions to our portfolio of products and services that help customers modernize their infrastructure and applications. Their capabilities will form the 'cornerstone' of our mainframe-to-GCP solutions, and customers are able to take advantage of these new capabilities now through our Professional Services Organization and our partner network," Weale wrote in his post announcing the deal. Reference Link

12:48 EST Seaspan updates progress on proposed reorganization - Earlier on Wednesday, Seaspan said that in November the company entered into an agreement to purchase a fleet of six containerships for approximately $380M in cash. Pro-forma to this acquisition, Seaspan's fully delivered global fleet of 119 vessels will reach approximately 975,000 TEU, representing a global market share of 7.7%, as measured by TEUs. Five of the six vessels were delivered in the fourth quarter, with the sixth vessel delivered on January 24. In November, Seaspan announced a proposed holding company reorganization to form Atlas, a new global asset management platform. The proposed reorganization will be implemented through the merger of Seaspan and an indirect, wholly-owned subsidiary, with Seaspan continuing as the surviving corporation and a direct, wholly-owned subsidiary of Atlas. The proposed reorganization is expected to advance the commitment of the Board of Directors and management to thoughtful capital allocation and diversification of cash flows through professional asset management. Bing Chen will be CEO and Ryan Courson will be CFO of Atlas Corp., as well as Seaspan. We've built a strong team equipped with core competencies to continue growing the container-shipping franchise and beyond. The proposed holding company reorganization to form Atlas Corp. is expected to provide us, as asset managers, with a solid foundation to expand our core competencies into power via the acquisition of APR Energy while augmenting our commitment to the container-shipping industry and customers. As we enter the second quarter of 2020, we believe that we are uniquely positioned to build on our strong momentum through a continued focus on our five key priorities."

12:23 EST Airbus presents plan to cut 2,362 positions in Defence and Space restructuring - Airbus Defence and Space has entered the consultation process with the company's European works council on the division's planned restructuring, the company announced. "While the underlying business perspectives especially in the core business remain solid, these steps became necessary after the division achieved a book-to-bill ratio below 1 for the third year in a row, mainly caused by a flat space market and postponed contracts on the defence side. The plans presented to the employee representatives foresee the reduction of 2,362 positions until end of 2021, thereof 829 in Germany, 357 in UK, 630 in Spain, 404 in France and 142 in other countries. These efforts will be supported by a reinforced profitability programme and further measures to increase long-term competitiveness and safeguard the division's future positioning. The need for restructuring was first announced in December 2019 and emphasized also during the company's Annual Press Conference in Toulouse on February 13. Airbus Defence and Space will provide updates on its plans and continues a constructive dialogue with employee representatives. Further financial implications are under assessment and will be communicated at a later stage," Airbus stated.

12:05 EST ResMed issues 'Class I recall' of ventilators, FDA reports - On December 5, 2019, ResMed sent a Field Safety Notification to customers informing them of a recall of Stellar ventilators because the sound alarm may fail to work, the FDA reported. "The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death," the agency stated in a new notice posted to its website. The model numbers affected are the 100 and 150 with a serial number range of 20160123307 to 22171057208. "The use of affected Stellar ventilators may cause serious adverse health consequences, including risk of serious injury or death. There has been one reported death," the FDA recall notice stated. Reference Link

12:01 EST Ally Financial falls -11.3% - Ally Financial is down -11.3%, or -$3.60 to $28.43.

12:01 EST Knoll falls -14.2% - Knoll is down -14.2%, or -$3.67 to $22.17.

12:01 EST Brookdale Senior Living rises 21.5% - Brookdale Senior Living is up 21.5%, or $1.49 to $8.42.

11:14 EST J.M. Smucker: Strategy includes review of all assets to evaluate underperformers - At the CAGNY Conference, J.M. Smucker said its strategy includes a review of "all tangible and intangible assets" to evaluate underperformers that need to be rationalized and their strategic fit within its portfolio.

10:58 EST J.M. Smucker rallies 2% to $111.49 amid CAGNY presentation

10:55 EST J.M. Smucker targets $1B in free cash flow - J.M. Smucker in CAGNY Conference presentation slides targeted $1B in free cash flow off a base of $850M in fiscal 2019.

10:04 EST SAP board proposes increased dividend, EUR1.5B in share buy backs - The Supervisory Board of SAP SE, in alignment with the Executive Board, has decided to recommend that shareholders approve a dividend of EUR1.58 per share for the fiscal year 2019. This represents a year-over-year increase of 5.3% compared to last year's dividend of EUR1.50. If the shareholders approve this recommendation at the Annual General Meeting of Shareholders on May 20, and based on the current number of shares carrying dividend rights, the total amount of dividends to be distributed will be approximately EUR1.89B, representing a pay-out ratio of 56%. The 2019 fiscal year dividend will be due for payment on May 26. The Supervisory Board also approved the Executive Board's decision to use the entire EUR1.5B of enhanced capital return for 2020 exclusively to buy back shares. The share buyback program will be executed based on the authorization granted by the SAP SE Annual General Meeting of Shareholders on May 17, 2018, and in compliance with the restrictions set forth therein. It will begin on February 20, 2020 and be finalized by December 31, 2020. "Our capital return policy ensures that our shareholders participate in our success," said CFO Luka Mucic. "The share buyback, in addition to an attractive regular dividend policy, is an important element in delivering shareholder value."

10:00 EST Sonic Automotive falls -12.8% - Sonic Automotive is down -12.8%, or -$3.95 to $26.95.

10:00 EST Sequans rises 11.3% - Sequans is up 11.3%, or 75c to $7.40.

10:00 EST Quad/Graphics rises 22.3% - Quad/Graphics is up 22.3%, or $1.14 to $6.23.

09:47 EST Fresh Del Monte falls -13.8% - Fresh Del Monte is down -13.8%, or -$4.68 to $29.33.

09:47 EST Knoll falls -16.8% - Knoll is down -16.8%, or -$4.33 to $21.51.

09:47 EST Sequans rises 11.1% - Sequans is up 11.1%, or 74c to $7.39.

09:40 EST Five Prime licenses antibodies to Seattle Genetics - Five Prime (FPRX) announced a global license agreement with Seattle Genetics (SGEN) to develop and commercialize novel antibody-drug conjugate, or ADC, therapies using monoclonal antibodies developed by Five Prime. ADCs harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Under the terms of the agreement, Five Prime granted Seattle Genetics an exclusive worldwide license to a family of monoclonal antibodies that are directed to a single target and Seattle Genetics will be responsible for research, development, manufacturing and commercialization of ADC products based on these antibodies. For the multi-product deal, Five Prime will receive a $5 million upfront payment and is eligible to receive progress-dependent development and regulatory milestone payments as well as cumulative commercial milestone payments. Cumulative milestones may reach up to $295 million for the first ADC product that is developed and commercialized. Five Prime will additionally receive tiered mid-single digit royalties on net product sales.

09:39 EST Adial Pharmaceuticals approved to commence Phase 3 trial of AD04 in Bulgaria - Adial Pharmaceuticals announced that it has received approval to commence its Phase 3 study to investigate AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder in Bulgaria in persons with certain target genotypes related to the serotonin transporter and receptor genes. This includes receiving approvals from both the Bulgarian Drug Agency and the Bulgarian Ethics Committee for Clinical Trials overseeing the study.

09:38 EST Lockheed Martin CEO says seeing 'significant' interest in F-35s overseas

09:37 EST Lockheed Martin CEO sees bipartisan support for U.S. defense spending growth - Comments taken from Citi's 2020 Global Industrials Conference.

09:34 EST Comtech announces service upgrade worth $1.2M - Comtech Telecommunications announced, that during its second quarter of fiscal 2020, its Location Technologies group, which is part of Comtech's Commercial Solutions segment, has finalized an agreement worth $1.2M for various location-based services with a provider of Public Safety services. This contract upgrades the provider from their current MLC platform to the latest cloud-native Virtual MLC platform to further extend the life of this critical component of their hosted E911 business for a contractual period of three years.

09:33 EST General Electric CEO says cash flow in Q1 'probably' in range of ($2B)

09:22 EST Pattern Energy issues letter to stockholders on Canada Pension Plan transaction - Pattern Energy's Board of Directors reiterated its recommendation that stockholders vote "for" the proposals relating to the company's pending transaction with Canada Pension Plan Investment Board at the upcoming Special Meeting. Highlights of the statement include: "The Pattern Energy Board firmly believes that proceeding with the transaction, which provides stockholders with significant, immediate and certain value, is advisable and is in the best interest of the company and its stockholders. Assertions on Pattern Energy's potential standalone price absent the CPP Investments transaction are speculative and down-play a number of key factors, including: The CPP Investments transaction monetizes Pattern Energy's growth prospects, including realizing the value of Pattern Development 2.0, at an attractive value. If it were to proceed standalone, the company would need to raise substantial equity in the public market to execute on its growth plan. The company has historically traded at a material discount to peers, which has made raising accretive equity challenging. In light of historic volatility in the sector, a short-term spike in prices should not be viewed as a reliable basis for predicting long-term value. The Board also believes unique events at certain other renewable energy companies have elevated their stock prices. (...) The CPP Investments transaction is the result of a robust process led by a Special Committee of the Pattern Energy Board, which considered multiple alternatives to the Company's standalone plan. (...) Each party that was contacted either did not respond or notified Pattern Energy that, after further review, it would not be interested in pursuing a potential transaction with Pattern Energy. (...) Pattern Energy continues to expect the transaction to close by Q2, subject to Pattern Energy stockholder approval, receipt of the required regulatory approvals, and other customary closing conditions".

09:14 EST Simian selects Kornit Atlas for scaling of direct-to-garment apparel decoration - Kornit Digital announces Simian is implementing the Kornit Atlas digital direct-to-garment system to increase its capacity for delivering sustainable, retail-ready decorated apparel on demand. Simian is the parent company of online print providing sites Reclameland, Drukland, and Flyerzone.

09:09 EST Diversicare to pay $9.5M to settle DOJ investigation - Diversicare Healthcare Services announced that it has resolved the investigation by the U.S. Department of Justice and the State of Tennessee. The investigation originated from a false claims action filed under seal in July 2012 relating to therapy services provided prior to that date, which is also before the current leadership team joined Diversicare. The final settlement resolved allegations related to the Company's practices and policies for rehabilitation and other services, for preadmission forms required by TennCare and for Pre-Admission Screening and Resident Reviews required by the Medicare program. Under the terms of the settlement, which are consistent with the Company's prior announcements and disclosures, Diversicare will pay a total of $9.5M over a five year period and could be required to make additional payments in the event the Company sells any of its owned facilities during this five year period. As a part of the settlement, the Company also entered into a Corporate Integrity Agreement with the Office of the Inspector General that will remain in place for the five year payment period. The Company continues to deny any wrongdoing in connection with the matters under investigation, but entered the settlement in order to avoid the uncertainty and expense of litigation and in order to focus on other initiatives.

09:04 EST Wanda Sports confirms preliminary discussions on potential IRONMAN sale - The company said, "While it is the policy of Wanda Sports Group Company not to comment on rumors in the marketplace or in media reports, in response to recent media speculation and noting recent appreciation in the price of its American Depositary Shares, the Company confirmed today that it is engaging in preliminary discussions concerning a potential sale of The IRONMAN Group."

09:02 EST WEC Energy increasing ownership interest in three Midwest wind farms - WEC Energy has agreed to increase its ownership interest from 80% to 90% in three Midwest windfarms: Blooming Grove Wind Farm, Thunderhead Wind Energy Center and the Upstream Wind Energy Center. The total investment is $118M for an additional 75 megawatts of capacity. Invenergy, a developer and operator of sustainable energy solutions, is currently building the Blooming Grove and Thunderhead projects which are expected to achieve commercial operation by the end of 2020. The Upstream Wind Energy Center, also developed by Invenergy, began service in January 2019. Under the tax rules, the WEC Energy Group investment is expected to be eligible for 100% bonus depreciation and production tax credits. The transactions are subject to receiving all necessary regulatory approvals.

08:59 EST Fly Intel: Pre-market Movers - HIGHER: Tesla (TSLA), up 7% after Piper Sandler analyst Alexander Potter raised the firm's price target on the stock to $928 from $729 and keeps an Overweight rating on the shares. The analyst says that in order to gauge Tesla's chances of success at storing one's own solar power, he recently installed a solar system to use for charging a Model X... Bed Bath and Beyond (BBBY), up 6% after announcing its FY20 capital allocation strategy, which will include an estimated $1B of spend balanced across capital return to shareholders, debt reduction and reinvestment in the company's core business operations to drive growth. UP AFTER EARNINGS: Dish (DISH), up 2%... Garmin (GRMN), up 9%... Enphase Energy (ENPH), up 14%. DOWN AFTER EARNINGS: NOW inc. (DNOW), down 8%... Scientific Games (SGMS), down 12%... Groupon (GRPN), down 29%. ALSO LOWER: Ally Financial (ALLY), down 10% after announcing that an agreement to acquire CardWorks in a transaction valued at approximately $2.65B... Blue Apron (APRN), down 10% after reporting Q4 earnings and announcing it will evaluate its strategic alternatives.

08:54 EST BioSig announces completion of 100 patient cases with PURE EP System - BioSig Technologies announced that the Company completed 100 patient cases with its PURE EP System. The Company initiated its first clinical trial in November 2019, and is currently enrolling patients at Texas Cardiac Arrhythmia Institute at St. David's Medical Center and Mayo Clinic's Florida campus. Earlier in 2019 the Company conducted patient cases at Indiana University School of Medicine, Greenville Memorial Hospital, Santa Barbara Cottage Hospital and Texas Cardiac Arrhythmia Institute at St. David's Medical Center. The Company's PURE EP System was used during the procedures on patients with persistent atrial fibrillation, ischemic ventricular tachycardias, PVC, atypical flutters and other types of complex arrhythmias.

08:47 EST Genuine Parts says Q4 total sales included 0.5% comparable growth - Sales for the fourth quarter were $4.7B, a 2.2% increase compared to $4.6B for the same period in 2018. Total sales included 0.5% comparable growth and approximately 6.7% from acquisitions, offset by a 4.2% decline due to the sale of EIS, Inc and Grupo Auto Todo and a 0.8% negative impact from foreign currency.

08:44 EST Genuine Parts reports Q4 SSS up 2.9% for Automotive Parts Group - Fourth quarter sales for the Automotive Group were up 8.7%, including an approximate 2.9% comparable sales increase, a 7.2% net benefit from acquisitions, divestitures and other adjustments and unfavorable foreign currency of 1.4%. Sales for the Industrial Group were down 5.9%, including a 1.2% comparable sales decrease and a 12.3% decrease due to the sale of EIS, partially offset by a 7.6% increase from acquisitions. Sales for the Business Products Group were down 6.3%.

08:43 EST Genuine Parts sees FY20 CapEx $275M-$325M - Sees FY20 net cash provided by operating activities $1B-$1.1B; Effective tax rate 24%-26%.

08:41 EST South Jersey Industries closes sale of Marina Thermal Facility - SJI (SJI) completed the previously announced sale of its Marina Thermal Facility to DTE Energy Services (DTE) for $100M, subject to certain adjustments for working capital, in cash. Consistent with SJI's stated goal of maintaining a strong balance sheet, the company intends to use proceeds from the sale to repay debt.

08:37 EST Enzo Biochem announces data indicating SK1-I reduced Lupus parameters published - Enzo Biochem announced the publication of a study in The FASEB Journal by academic researchers that shows drug candidate SK1-I, the company's proprietary Sphingosine Kinase 1 inhibitor, markedly reduced Lupus-associated parameters in a recognized, chemically-induced animal model of Systemic Lupus Erythematosus, commonly known as Lupus. This treatment resulted in reductions in interferon, or IFN, signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney. Significantly, SK1-I was not only effective when administered simultaneously with the chemical induction of Lupus in this model, but was also effective when administered 30 days after the chemical induction of the disorder. In further confirmation that the effects of SK1-I in the Lupus model are the result of inhibiting the enzyme Sphingosine Kinase 1, the effects were mirrored by genetic deletion of the enzyme. These results suggest that SK1-I may have potential in the treatment of Lupus.

08:34 EST Seattle Genetics and Astellas combination granted FDA Breakthrough Therapy - Astellas Pharma (ALPMY) and Seattle Genetics (SGEN) announced that the FDA has granted Breakthrough Therapy designation for Padcev in combination with Merck's (MRK) anti-PD-1 therapy Keytruda for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. The Breakthrough Therapy designation was granted based on results from the dose-escalation cohort and expansion cohort A of the phase 1b/2 trial, EV-103, evaluating patients with locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy treated in the first-line setting with Padcev in combination with pembrolizumab. EV-103 is an ongoing, multi-cohort, open-label, multicenter phase 1b/2 trial of Padcev alone or in combination, evaluating safety, tolerability and efficacy in muscle invasive, locally advanced and first- and second-line metastatic urothelial cancer.

08:30 EST FactSet expands Canadian content coverage - FactSet announced that it is expanding its content offering in Canada. This expansion includes the launch of Canadian-specific coverage from StreetAccount, the real-time market intelligence news service, as well as investment fund information from Fundata Canada. StreetAccount provides real-time company and sector news that matter to the investment industry. Its team of writers consists of previous industry professionals who use their experience as portfolio managers, analysts, and traders to report the stories that are important for investors. By expanding into Canada, StreetAccount now provides clients with real-time news, start- and end-of-day market summaries, and tailored alerts for all companies trading on the TSX, TSX Venture, and Canadian Securities Exchange with a market cap of CA$25 million or higher.

08:29 EST Qorvo completes acquisition of Custom MMIC - Qorvo announced that it has completed its acquisition of Custom MMIC, a supplier of high-performance GaAs and GaN monolithic microwave integrated circuits for defense, aerospace and commercial applications. As part of Qorvo's Infrastructure and Defense Products business, the Custom MMIC team will continue to expand its millimeter wave capabilities for products used in defense phased array and AESA radars, electronic warfare, satellite communications, wireless backhaul and microwave test equipment. Chelmsford, Massachusetts-based Custom MMIC was founded in 2006 and has extensive experience developing MMICs at frequencies up to 70 GHz. Custom MMIC adds small signal mmWave expertise and a portfolio of more than 180 standard products including LNAs, mixers, attenuators, phase shifters and switches. Custom MMIC president and CTO Paul Blount joins Qorvo as a director of engineering for Infrastructure and Defense Products.

08:26 EST Poet Technologies confirms receipt of scheduled payment - POET Technologies confirmed that it had received a scheduled payment from the Buyer of DenseLight. In connection with the sale of DenseLight, its Singapore-based subsidiary, POET confirmed that it had received the scheduled Tranche 2a payment of $4.75M, despite the recent business interruptions in China resulting from COVID-19. The Company has initiated the transfer of an additional 19% of DenseLight shares from escrow to the Buyer. It also confirmed that the 2b payment of $8.25M, which will transfer an additional 32% to the Buyer is on track to be paid by the end of March 2020. In connection with his appointment as Lead Independent Director in November 2019, the Board of Directors granted Peter Charbonneau options to purchase 35,488 common shares of the Company. The options are exercisable for 10 years at a price of C$0.42, being the closing price of the Company's common stock on Wednesday, February 5, 2020. 25% of the options will vest immediately, with the remaining options vesting quarterly through October 2020. All the options were granted subject to provisions of the Company's stock option plan and are subject to the TSX Venture Exchange policies and applicable securities laws. For further details on the Company's share capital, refer to the Company's Financial Statements and MD&A for the period ended September 30, 2019, which were filed on SEDAR on November 21, 2019. Additionally, POET announced the planned opening of an office and lab in Allentown, Pennsylvania on April 1, 2020. Concurrently, the Company has taken the required actions to close its office in San Jose, California.

08:24 EST Ekso Bionics says PAM acquires three additional EksoNR devices - Post Acute Medical has acquired three additional EksoNR devices from Ekso Bionics to expand the availability of exoskeleton-assisted rehabilitation to seven of its facilities. The new EksoNR devices will be placed in Kyle and Clear Lake, Texas and Tulsa, Oklahoma. Exoskeleton-assisted rehabilitation is now available at five PAM locations in Texas. The device is designed to help patients stand and walk during rehabilitation after a stroke or spinal cord injury.

08:22 EST New Age Beverages launches Noni+CBD in Japan - NewAge Beverages announced the launch of their CBD beverage Noni+CBD in Japan through their network of more than 50,000 independent distributors. NewAge's Noni+CBD product is the first CBD beverage from any major company to gain approval by the Japanese Ministry of Health and the Japanese Narcotics Control Division for sale in the country. NewAge began working with the Ministry of Health in early 2019 to provide testing data and quality control and manufacturing practices information for its 0.0% THC CBD product, which culminated in the recent approval. The Noni+CBD product that was launched this week is a 50ml shot of Tahitian Noni Juice, emulsified with a 25mg dose of CBD, deemed to be safe for consumption by the Japanese regulatory authorities and effective for consumers.

08:17 EST LiveXLive Media appoints Jackie Stone Chief Marketing Officer - LiveXLive Media has appointed Jackie Stone Chief Marketing Officer of LiveXLive. Stone's background includes more than 28 years of marketing leadership at diverse companies such as Madison Square Garden, MSNBC, About.com, Digitas and AOL. An adjunct professor at the New York University School of Professional Studies, she earned an MBA at the University of Miami.

08:16 EST Aspen Group reports 1,746 enrollments in Q3 - Aspen Group announced third quarter new student enrollments of 1,746 in fiscal 2020 third quarter ending January 31, 2020, an increase of 28% year-over-year. Quarterly bookings increased 72% year-over-year from $15.5 million to $26.5 million. Consequently, total bookings for the first nine months of fiscal 2020 was $84.7 million, which on a run rate basis is on track to meet or exceed the company's forecast for fiscal 2020 bookings growth of 54% to $102M. For the third quarter of fiscal year 2020, Aspen University accounted for 1,371 new student enrollments delivering overall enrollment growth at Aspen University of 23% year-over-year. Enrollment growth at Aspen University was driven primarily by the Pre-Licensure BSN program as a result of a full quarter of enrollments at both Phoenix, AZ campuses, as compared to the prior year with only one campus open. United States University accounted for 375 new student enrollments in the quarter driven primarily by MSN-Family Nurse Practitioner enrollments, a 49% enrollment increase year-over-year. The improved year-over-year MER results were driven by declining cost of enrollment. Compared to the previous year, AGI's weighted average cost of enrollment declined 28%, from $1,373 to $989. On a year-over-year basis, fiscal Q3'20 bookings increased 72%, from $15.5 million to $26.5 million, delivering a company-wide average revenue per enrollment increase of 34%, from $11,352 to $15,199. AGI's overall active student body grew 32% year-over-year from 8,354 to 11,033. Aspen University's total active degree-seeking student body grew 25% year-over-year from 7,393 to 9,274. Aspen University students paying tuition and fees through a monthly payment method grew by 13% year-over-year, from 5,259 to 5,966, representing 64% of Aspen University's total active student body. On a year-over-year basis, USU's total active student body grew from 961 to 1,759 or 83%. USU students paying tuition and fees through a monthly payment method grew from 1,101 to 1,159 students sequentially representing 66% of USU's total active student body.

08:12 EST Eton says FDA requests changes to ET-105 Dosage and Administration section - Eton Pharmaceuticals provided an update on its ET-105 product candidate, which is currently under review with the U.S. Food and Drug Administration. In a review correspondence and a teleconference held yesterday, the FDA requested that Eton and its development partner make changes to the Dosage and Administration section of the product's Prescribing Information to simplify the dosing information for intended users. The FDA has requested that the company conduct a human factors validation study with the revised labeling to demonstrate that the intended users can prepare and administer the oral suspension safely and effectively. Eton remains confident that it can successfully complete the requested human factors validation study, however, the study is unlikely to be completed by the product's March 17, 2020 Prescription Drug User Fee Act date. The company expects the study and its final report to be completed and submitted to the FDA in the coming months. Eton is not aware of any other non-labeling related deficiencies outstanding with the FDA's review and believes the NDA will be approved in 2020.

08:10 EST Immutep announces interim data from ongoing Phase II TACTI-002 study - Immutep announces interim data from its ongoing Phase II TACTI-002 study. The results are being presented today at the 34th German Cancer Congress in Berlin by Principal Investigator, Dr. Bernhard Doger of START Madrid, Spain. The Company will also present this interim data and provide a further update on its clinical programs in a global webcast. The data relates to use of the Company's lead product candidate eftilagimod alpha, a soluble LAG-3 protein, as part of a combination treatment with pembrolizumab. The activation of antigen-presenting cells and subsequent T cell recruitment with efti may lead to stronger anti-tumour responses than observed with pembrolizumab alone. TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA. It is evaluating the combination of efti with MSD's KEYTRUDA in up to 109 patients. All patients receive 200 mg of pembrolizumab every three weeks, along with 30 mg of efti every two weeks for the first eight cycles and every 3 weeks thereafter. The trial is a Simon's two-stage, open-label, single-arm study, with patients participating in three Parts. TACTI-002 is an all comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC. PD-L1 expression is typically reported in three groups for NSCLC: less than 1%, 1-49% and greater than or equal to50%. Patients with a high PD-L1 status are typically more responsive to anti-PD-1 monotherapy such as pembrolizumab, whereas those with low PD-L1 status are overall significantly less responsive. Pembrolizumab monotherapy is registered in the US and the EU for first-line NSCLC patients with a TPS score greater than or equal to1% and greater than or equal to50%, reflecting 65% and 30% of all first line NSCLC patients, respectively. Overall Response Rate of 47% and no patient with a response had progressive disease thus far. Distribution of the PD-L1 subgroups is as expected a ~30% with greater than or equal to 50% PD-L1. Tumour responses are reported across all three PD-L1 expression level groups for NSCLC. 5 out of the 8 responders had a PD-L1 expression less than50%. Majority of NSCLC patients are still under treatment and median PFS is not yet reached with all patients having passed the 7+ months mark already. Interim ORR of 33% with 6 out of 18 patients reporting a response according to iRECIST. More detailed data will be provided as patient treatment duration advances. No new safety signals for this combination therapy reported thus far. Recruitment is ongoing for stage 1 of Part B, along with stage 2 of Parts A and C.

08:07 EST Tech Data expands AWS cloud support capabilities with nOps partnership - Tech Data (TECD) announced that it has partnered with nOps, a provider of a software-as-a-service, or SaaS, cloud management platform for Amazon (AMZN) Web Services, or AWS. The nOps solution offering will empower Tech Data's U.S. partners to help their end-user customers build, manage, and run secure and optimized AWS infrastructures. It will also ensure Tech Data partners can maintain their customers through continuous alignment with the AWS well-architected framework and other industry best practices.

08:06 EST resTORbio announces interim results for Phase 1b/2a trial of RTB101 - resTORbio announced interim results from the ongoing Phase 1b/2a trial of RTB101, an orally-administered small molecule potent target of rapamycin complex inhibitor product candidate, alone or in combination with sirolimus, in Parkinson's disease. The multicenter, 2:1 randomized, double-blind, placebo-controlled Phase 1b/2a trial is evaluating the safety and tolerability of RTB101 alone or in combination with escalating doses of sirolimus once weekly for 4 weeks in patients with Parkinson's disease. To date, patients have been enrolled in three cohorts and dosed once weekly with 300 mg of RTB101 alone, 2 mg of sirolimus alone, or a combination of 300 mg RTB101 and 2 mg of sirolimus. Results of the interim study analysis indicated that all 3 dosing regimens were well tolerated and RTB101 300 mg once weekly was observed to cross the blood brain barrier. The concentrations of RTB101 in cerebrospinal fluid in subjects dosed with RTB101 300 mg once weekly monotherapy were higher than expected and based on preclinical models, have the potential to induce autophagy in the brain. Sirolimus at the dose of 2 mg, alone or in combination with RTB101, was not detected in the CSF. Data from the first three cohorts in the study suggest that the concentrations of RTB101 observed in the CSF four hours after dosing were highest when RTB101 was given as a monotherapy. Enrollment of the RTB101 300 mg in combination with sirolimus 4 mg once weekly cohort is ongoing.

08:04 EST Cellectar says CLR 131 achieves primary efficacy endpoints in Phase 2 study - Cellectar Biosciences announced data from its Phase 2 CLOVER-1 study in patients with relapsed/refractory B-cell lymphomas. Additionally, the company announced the successful completion of its Phase 1 dose escalation study. Data from the studies demonstrated activity in all indications tested: multiple myeloma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma and lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. CLR 131 achieved notable response rates in patients with multiple myeloma - 34.5% overall response rate over all therapeutic doses, and non-Hodgkin's lymphoma - 42% ORR over all doses while maintaining a well-tolerated safety profile across all patients. Based upon these positive results and corroborating data showing the potential to further improve upon current overall response rates and durability of those responses, the study has been expanded to test a two-cycle dosing optimization regimen of CLR 131. Patients in the studies were heavily pre-treated, with multiple myeloma patients having a median of five prior treatment regimens, which included immunomodulatory drugs, proteasome inhibitors and CD38 antibodies for the majority of patients. Additionally, a majority of the patients were quad refractory or greater and 44% of all treated multiple myeloma patients were triple class refractory. NHL patients in the study were also heavily pre-treated, having had a median of 3 prior lines of treatment with the majority of patients being refractory to rituximab and/or ibrutinib. In both groups, the patients had a median age of 70 with a range of 51 to 86. Relapsed/refractory multiple myeloma patients were treated with three different doses; the less than50mCi total body dose was a deliberately planned sub-therapeutic dose. Patients who received the highest dose of CLR 131 showed a 42.8% ORR, and those who received ~50mCi TBD had a 26.3% ORR with 100% of all evaluable patients achieving clinical benefit as defined by having stable disease or better. 85.7% of multiple myeloma patients receiving the higher total body dose levels of CLR 131 experienced tumor reduction. The 75mCi TBD demonstrated positive activity in both high-risk patients and triple class refractory patients with a 50% and 33% ORR, respectively. The most frequently reported adverse events in relapsed/refractory multiple myeloma patients were cytopenias, which followed a predictable course and timeline. The most common grade greater than or equal to3 events at the highest dose were hematologic toxicities including thrombocytopenia, neutropenia, leukopenia, anemia and lymphopenia. No patients experienced cardiotoxicities, neurological toxicities, infusion site reactions, peripheral neuropathy, allergic reactions, cytokine release syndrome, keratopathy, renal toxicities, or changes in liver enzymes. The safety and tolerability profile in patients with relapsed/refractory NHL was the same except for fewer cytopenias of any grade. In addition to these findings, subtype assessments were completed in the r/r B-cell NHL patients. Patients with DLBCL demonstrated a 30% response rate with one patient achieving a complete response, which continues at nearly 24 months post-treatment. The response rate for CLL/SLL/MZL patients was 33%. Only two mantle cell patients were enrolled, with stable disease as the best response. Current data from the company's Phase 2 CLOVER-1 clinical study show that four LPL/WM patients demonstrated 100% ORR with one patient achieving a complete response which continues at nearly 27 months. This may represent an important improvement in the treatment of relapsed/refractory LPL/WM as no approved or late-stage development treatments for second- and third-line patients have reported a complete response. LPL/WM is a rare, indolent and incurable form of non-Hodgkin's lymphoma that is comprised of a niche patient population in need of new and better treatment options.

07:50 EST Emergent BioSolutions enters into Narcan settlement agreement with Perrigo - In a regulatory filing yesterday, Emergent BioSolutions (EBS) disclosed that the Company, through its Adapt Pharma subsidiaries, filed complaints, in 2016 against Teva Pharmaceuticals Industries (TEVA) and in 2018 against Perrigo (PRGO), relating to Teva's and Perrigo's respective abbreviated new drug applications seeking to market generic versions of Narcan Nasal Spray 4mg/spray. On February 12, 2020, Adapt and Perrigo entered into a settlement agreement to resolve the ongoing litigation. Under the terms of the settlement, Perrigo has received a non-exclusive license under Adapt's patents to make, have made and market its generic naloxone hydrochloride nasal spray under its own ANDA. Perrigo's license will be effective as of January 5, 2033 or earlier under certain circumstances including circumstances related to the outcome of the current litigation against Teva or litigation against future ANDA filers. The Perrigo settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey. Closing arguments in the Teva trial are scheduled for February 26, 2020. Adapt also filed a complaint related to Teva's ANDA seeking to market a generic version of Narcan Nasal Spray 2mg/spray and that matter is still pending, Emergent noted.

07:37 EST VIVUS announces commercial launch of Qysmia in Republic of Korea - VIVUS announced that its Korean marketing partner, Alvogen, has launched Qsymia in the Republic of Korea. Under an agreement executed in September 2017, Alvogen is solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea. In addition to the upfront payment that VIVUS received at the time the agreement was executed and the milestone payment received upon approval of Qsymia by the South Korea Ministry of Food and Drug Safety in August 2019, VIVUS will receive a $2M payment tied to the commercial launch of Qsymia. Under the agreement, VIVUS is also eligible to receive royalties on Alvogen's net sales of Qsymia and future milestone payments contingent upon achievement of net sales goals within the covered territory.

07:35 EST Wayfair names Kelly Clarkson as first official brand ambassador - Wayfair announced that singer, songwriter, trusted voice coach and TV host Kelly Clarkson will serve as the retailer's first official brand ambassador in the U.S. "The all-new, integrated partnership with Clarkson, which spans TV, digital and retail, aims to empower Wayfair customers to shop confidently while exploring the unlimited possibilities in home. In April, Wayfair and Clarkson will release an exclusive, two-part collection of furniture, decor and more, inspired by her lifestyle and southern roots. Spanning beautiful pieces for the whole home, the line will offer everything from bedroom sets and armoires, to dining tables, bar carts, chandeliers and more."

07:33 EST Wingstop reports Q4 domestic SSS up 12.2%

07:26 EST Garmin intends to increase quarterly dividend 7% to 61c per share - The board of directors of Garmin intends to recommend to the shareholders for approval at the annual meeting to be held on June 5, a cash dividend in the amount of $2.44 per share, payable in four equal installments on dates to be determined by the board. The board currently anticipates the scheduling of the dividend in four installments. In addition, the board of directors has established March 31 as the payment date and March 16 as the record date for the final dividend installment of 57c per share, per the prior approval at the 2019 annual shareholders' meeting.

07:17 EST Rockwell Automation to acquire ASEM, terms undisclosed - Rockwell Automation announced it has signed an agreement to acquire Italy-based ASEM, a provider of digital automation technologies. ASEM provides a range of Industrial PCs, or IPCs, human-machine interface, or HMI, hardware and software, remote access capabilities, and secure Industrial IoT gateway solutions. ASEM's automation solutions enable The Connected Enterprise with technology, productivity and a more secure environment by integrating smart devices, the control platform, and design and operational software all on a single network. The transaction includes the purchase of a minority interest in ASEM held by KEB Group, Germany. Post-close, Rockwell Automation will maintain ASEM's strategic supplier and technology partner relationship with KEB. The transaction is expected to close in the spring of 2020, subject to customary approvals and conditions, and will be reported in the architecture and software business segment. Rockwell Automation will provide additional information at the upcoming Barclays and Citi investor conferences.

07:16 EST First Majestic reports Q4 total production of 6.2M silver equivalent ounces - Produced 3.3 million ounces of silver, 33,176 ounces of gold and 0.9 million pounds of lead for a total of 6.2 million silver equivalent ounces.

07:11 EST Akoustis announces development order for C-band XBAW filter - Akoustis Technologies announced a development order for a new C-band XBAWTM filter that will be used in Unmanned Aircraft Systems for control and non-payload communication links. Under the new purchase order, Akoustis will develop and deliver samples of the XBAW filter for the UAS application by the end of September 2020 for testing and evaluation. The Company expects it will be able to deliver qualified XBAWTM filters and expects to receive orders for commercial product by the end of March 2021.

07:09 EST Nokia to acquire Elenion, terms not disclosed - Nokia announced plans to acquire Elenion Technologies, a U.S.-based company focusing on silicon photonics technology. Elenion's technology expertise and unique design platform and services enable Nokia to expand its market footprint by addressing the critical and rapidly evolving optical connectivity requirements of 5G, cloud and enterprise networking. Ownership of these key assets brings time-to-market and cost advantages to Nokia's broad portfolio of networking solutions by applying the massive scale and economies of silicon design and manufacturing to the optical supply chain. Elenion develops highly integrated, low-cost silicon photonics technologies for short-reach and high-performance optical interfaces and has pioneered a design toolset which enables a greatly simplified, low cost, scalable manufacturing process. The Elenion platform simplifies integration with optical chipsets, lowers power consumption, improves port density and helps to lower the overall cost per bit for network operators. Elenion was founded in 2014 and is privately held and headquartered in New York, NY. The planned transaction is expected to close in Q1 2020, subject to regulatory approvals and customary closing conditions.

07:06 EST Canadian Solar begins construction on 26.6 MWp of solar power plants in Japan - Canadian Solar has commenced construction on two solar PV power projects in Japan. The first is a 13.6 MWp project in the Ibaraki Prefecture. Once in operation, the plant is expected to generate approximately 15,901 MWh of solar electricity each year, which will be purchased by Tokyo Electric Power under a 20-year feed-in-tariff contract. The company expects the project to reach commercial operation by mid-2021. The second project is a 13.0 MWp project in the Fukuoka Prefecture. The plant is expected to generate approximately 15,250 MWh of solar energy each year, which will be purchased by Kyushu Electric Power under a 20-year feed-in-tariff contract. The project is also expected to reach commercial operation by mid-2021.

07:05 EST Optinose appoints Victor Clavelli as CCO - Optinose (OPTN) announced the appointment of Victor Clavelli as chief commercial officer. Clavelli joins Optinose from Pfizer (PFE) where, in the course of an accomplished 20-year career, he held leadership roles including marketing, sales, and regulatory affairs. Most recently, he served as the North American President for Inflammation and Immunology with responsibility for a portfolio spanning topical, small molecule oral, and biologic agents.

07:04 EST CytoSorbents enters agreement with China Medical System Holdings - CytoSorbents and China Medical System Holdings entered into an agreement to bring CytoSorb to mainland China to treat critically-ill patients with COVID-19 coronavirus infection. Under the terms of the agreement, CytoSorbents and CMS will partner together to earn regulatory clearance to import CytoSorb into China under the "fast-track" review process established by the National Medical Products Administration of the People's Republic of China to respond to the 2019 novel coronavirus pandemic. CytoSorbents will donate initial CytoSorb devices and provide product, training, and support to CMS to introduce CytoSorb initially into four hospitals in the Wuhan, China area. The therapy will be evaluated in severe COVID-19 coronavirus patients with a systemic inflammatory response who are being treated with either continuous renal replacement therapy or extracorporeal membrane oxygenation. During the initial term of the agreement, CytoSorbents and CMS will explore the possibility for future commercial collaboration in China. The financial terms of the agreement have not been disclosed.

07:03 EST Houston American Energy reports San Andres drilling plans and increased interest - Houston American Energy announced drilling plans for the company's second San Andres well in Yoakum County, the Frost #2-H well. The operator has set a drilling date for March, 2020, pending rig availability. The prospect contains 650 gross acres. Houston American has increased its working interest in the planned well from 12.5% to 18.6%. The initial Yoakum County well, Frost #1-H, is commercially productive.

07:02 EST Matinas BioPharma announces DSMB approval to begin Part 2 of EnACT study - Matinas BioPharma announced that the independent Data Safety Monitoring Board for the EnACT study has completed its planned review of initial safety and tolerability data from the Part 1 dose escalation phase and unanimously approved proceeding with enrollment in the Part 2 efficacy phase at 2g of MAT2203 daily, the highest dose tested in Part 1. The 2g dose will be tested in the 2-week induction phase of treatment. Data from Part 1 demonstrated that MAT2203 was safe and well tolerated across all three daily doses tested. Part 2 of the EnACT study will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. EnACT is an open-label, sequential cohort study, financially sponsored by the National Institutes of Health with David Boulware, M.D., M.P.H, Professor of Medicine at the University of Minnesota acting as principal investigator for the study in collaboration with Dr. David Meya, Ph.D. of Makerere University. This trial utilizes MAT2203, which applies the Company's LNC drug delivery technology to orally deliver amphotericin B, an otherwise IV-only, highly toxic, fungicidal drug for the treatment of HIV-patients with cryptococcal meningitis. Oral MAT2203 is designed to target delivery directly to infected tissues, protecting the body from unnecessary exposure to amphotericin B, and is expected to be a safer alternative to the traditional IV-forms of this highly potent drug with a lower propensity for kidney toxicity. The study consists of two distinct parts; Part 1 is designed to determine the maximum tolerated dose among people living with HIV but who do not have a fungal infection. Part 2 is a prospective randomized trial evaluating the safety, tolerability and efficacy of MAT2203 in HIV-infected patients with cryptococcal meningitis, compared to treatment with standard IV-administered amphotericin B as induction therapy. As previously reported, the Food and Drug Administration has designated MAT2203 as a Qualified Infectious Disease Product with Fast Track status for four indications, specifically, the prevention of invasive fungal infections due to immunosuppressive therapy, and the treatment of invasive candidiasis, invasive aspergillus and cryptococcal meningitis. In addition, the FDA granted orphan drug designation to MAT2203 for the treatment of cryptococcosis.

06:48 EST BankUnited provides update on share repurchase program - For the period January 1 through February 14, the company repurchased 1,048,414 shares of its outstanding common stock for an aggregate purchase price of approximately $35.4M, at a weighted average price of $33.74 per share. To date, under the $150M purchase program authorized by its Board of Directors in September 2019, the company has repurchased 1,171,590 shares of its outstanding common stock for an aggregate purchase price of approximately $39.4M, at a weighted average price of $33.63 per share.

06:35 EST Co-Diagnostics announces new orders for vector control tests - Co-Diagnostics announced that it has received new orders for its vector control tests and equipment from mosquito abatement districts following attendance at several vector control conferences. Co-Diagnostics has recently added new mosquito abatement customers in the Eastern United States as well as the Midwest. Significantly, the company offers tests tailored to all regions of the country, including multiplexed tests that include either eastern equine encephalitis or western equine encephalitis, depending on the abatement district location. As a result of the conference presentation and exhibition, the company received broad domestic and international interest in its products.

06:15 EST Genesis Energy sees 2020 adjusted EBITDA $640M-$680M - Sees 2020 offshore pipeline transportation segment to be $20M-$30M above 2019 levels. The marine transportation segment is budgeted to improve some $2M-$6M.

06:10 EST National Health Investors increases quarterly dividend 5% to $1.10 per share - National Health Investors announced that it will increase its quarterly dividend by 5% to $1.10 per common share. Dividends are payable on May 8 to shareholders of record as of March 31.

05:42 EST ICL announces acquisition of Growers Holdings - ICL announced that it has acquired Growers Holdings. Growers' agronomic services platform enhances decision-making capabilities for farmers, agronomists and other agro-professionals by creating easily adaptable and executable data-driven recommendations.

05:14 EST Eaton forms joint venture with Abunayyan Holding - Eaton and Abunayyan Holding announced the formation of a joint venture to produce and service low- and medium-voltage switchgear in the Middle East. The joint venture will do business as Eaton Arabia and will have locations in Dammam, Saudi Arabia, and Dubai, United Arab Emirates. Abunayyan and Eaton will each own 50 percent of the new joint venture, and Abunayyan will consolidate joint venture results.

04:57 EST Diamondback Energy doubles dividend to $1.50 per year - Diamondback Energy said last night that its board approved a 100% increase in its annual cash dividend policy to $1.50 per common share starting with Q4 payment. The company's board declared a cash dividend of 37.5c per common share for Q4, payable on March 10, to stockholders of record at the close of business on March 3.